Avalyn Pharma Inc. - 8-K Filing

Avalyn Pharma reports Q3 2026 net loss of $29.7 million and initiates Phase 1 study for AP03 combination therapy. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 12, 2026, 13:08 UTC

Tickers: $AVLN

Read the full article at SEC EDGAR

Part of the story DATA I/O CORP - 8-K Filing (3 articles)

More Regulatory news

FILANA THERAPEUTICS, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 13:18 UTC
RUM Group Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:17 UTC
Theriva Biologics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SeaStar Medical Holding Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
Avalyn Pharma Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SES AI Corp - 8-K Filing SEC EDGAR · November 12, 2026, 13:15 UTC
Data443 Risk Mitigation, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:15 UTC
TRUSTMARK CORP - 8-K Filing SEC EDGAR · November 12, 2026, 13:15 UTC
SUBURBAN PROPANE PARTNERS LP - 8-K Filing SEC EDGAR · November 12, 2026, 13:14 UTC
MeiraGTx Holdings plc - 10-Q Filing SEC EDGAR · November 12, 2026, 13:13 UTC